Prospect News: News for Oxygen Biotherapeutics, Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with O > Issuers starting with O, PP only > All stories on Oxygen Biotherapeutics, Inc. > Stories on Oxygen Biotherapeutics, Inc., PP only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Oxygen Biotherapeutics, Inc.

3/24/2014	PP	Oxygen greenshoe exercised for $59.8 million public offering of stock
3/18/2014	PP	Oxygen Biotherapeutics prices $52 million public stock sale at $5.60
3/17/2014	PP	Oxygen Biotherapeutics plans to sell common stock in public offering
8/13/2013	PP	Oxygen Biotherapeutics plans $4.6 million convertible preferreds sale
7/22/2013	PP	Oxygen Biotherapeutics prices $5.37 million public sale of preferreds
7/17/2013	PP	Oxygen Biotherapeutics to sell 6,000 preferreds in public offering
3/22/2013	PP	Oxygen Biotherapeutics aims to sell preferred units in public offering
2/25/2013	PP	Oxygen Biotherapeutics details $2.1 million preferred stock offering
2/22/2013	PP	Oxygen Biotherapeutics negotiates $1.6 million public preferreds sale
6/15/2012	PP	Oxygen Biotherapeutics amends $7.5 million convertible preferreds sale
12/9/2011	PP	Oxygen Biotherapeutics plans $7.5 million convertible preferreds sale
7/1/2011	PP	Oxygen Biotherapeutics concludes $4.9 million sale of 15% convertibles
6/22/2011	PP	Oxygen Biotherapeutics completes $4.6 million sale of 15% convertibles
5/4/2010	PP	New Issue: Oxygen Biotherapeutics arranges $5 million direct offering of stock
5/4/2010	PP	Market Commentary: Suroco prices C$50 million offering; Perseus seeks A$29 million; Brainspark sells convertibles
6/8/2009	PP	New Issue: Oxygen Biotherapeutics announces $5 million share placement, warrant exchange offer

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.